CYBB Gene Immunodeficiency Type 34 NGS Genetic DNA Test
Comprehensive Genetic Testing for Chronic Granulomatous Disease
The CYBB Gene Immunodeficiency Type 34 NGS Genetic DNA Test represents a breakthrough in molecular diagnostics for immune system disorders. This advanced genetic analysis specifically targets mutations in the CYBB gene, which encodes the gp91-phox subunit of the NADPH oxidase complex. When this gene malfunctions, it leads to Chronic Granulomatous Disease (CGD), a rare inherited immunodeficiency that significantly impacts the body’s ability to combat bacterial and fungal infections.
What This Test Measures and Detects
Our Next-Generation Sequencing (NGS) technology provides comprehensive analysis of the CYBB gene to identify:
- Point mutations, deletions, and insertions in the CYBB gene
- X-linked recessive inheritance patterns
- Pathogenic variants affecting NADPH oxidase function
- Genetic markers associated with immunodeficiency type 34
- Carrier status for family members
Who Should Consider This Test
This genetic test is particularly recommended for individuals experiencing:
- Recurrent bacterial and fungal infections despite treatment
- Unexplained granuloma formation in various organs
- Family history of Chronic Granulomatous Disease
- Persistent lymphadenopathy or hepatosplenomegaly
- Diagnostic uncertainty in immunodeficiency cases
- Children with failure to thrive and recurrent infections
- Patients with autoimmune manifestations alongside infections
Key Benefits of CYBB Gene Testing
Choosing our comprehensive genetic analysis provides numerous advantages:
- Early Diagnosis: Identify genetic mutations before severe complications develop
- Personalized Treatment: Guide targeted therapies and prophylactic measures
- Family Planning: Provide crucial information for genetic counseling
- Improved Outcomes: Enable proactive management of immunodeficiency
- Comprehensive Analysis: NGS technology ensures thorough mutation detection
- Expert Interpretation: Results reviewed by certified genetic specialists
Understanding Your Test Results
Our genetic counselors provide detailed interpretation of your results:
- Positive Result: Indicates presence of pathogenic CYBB gene mutation, confirming Chronic Granulomatous Disease diagnosis
- Negative Result: No detected mutations, though clinical correlation remains essential
- Variant of Uncertain Significance: Requires additional family studies and clinical evaluation
- Carrier Status: Important for family members and reproductive planning
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | CYBB Gene Immunodeficiency Type 34 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
Pre-Test Requirements
Before scheduling your test, please ensure:
- Complete clinical history documentation
- Genetic counseling session to create family pedigree chart
- Discussion of testing implications with healthcare provider
- Understanding of potential results and their significance
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified genetic testing facilities ensures accessibility and consistent quality standards nationwide.
Take Control of Your Health Today
Don’t let uncertainty about immune system disorders compromise your quality of life. Our CYBB Gene Immunodeficiency Type 34 NGS Genetic DNA Test provides the clarity needed for proper diagnosis and management. Early detection can significantly improve treatment outcomes and quality of life for individuals with Chronic Granulomatous Disease.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic test consultation and take the first step toward comprehensive immune system evaluation.
